6533b82efe1ef96bd12932d8
RESEARCH PRODUCT
Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patients: Fast Pain Relief.
Carlo PavoneSalvatore RomeoFrancesco D'amatoManuela UsalaGiulia Letizia MauroGiovanni CaruanaGiovanni Caruanasubject
Malemedicine.medical_specialtyTime FactorsVisual analogue scalePeyronie's diseaseUrologyPenile Induration030232 urology & nephrologyPain reliefPainElectric Stimulation TherapyElectric Capacitance03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesElectric ImpedanceMedicineHumansSingle-Blind MethodAdverse effectPenile painAgedPain MeasurementResistive touchscreenErectile failure; Induratio penis plastic; Penile pain; Penis plaque; Peyronie's disease; Transfer capacitive resistive energy; Urology030219 obstetrics & reproductive medicinebusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaPenile ErectionInduratio penis plasticTransfer capacitive resistive energyTherapeutic effectRecovery of FunctionMiddle Agedmedicine.diseaseTreatment OutcomeTolerabilityItalyPhysical therapyPenile painPeyronie's diseasebusinessErectile failurePenis plaquePenisdescription
<b><i>Background/Aims/Objectives:</i></b> We have investigated the clinical and physiological effects of Transfer Capacitive Resistive Energy (TCARE) therapy on men with Peyronie's disease (PD). <b><i>Methods:</i></b> Ninety-six men with PD have been randomized in a 2:1 ratio to receive 3 sessions of TCARE therapy or sham therapy. Pain, penile curvature and erectile function have been assessed before the first treatment and up to 9 months after the end of treatment, using the Visual Analogue Scale for the pain, a goniometer to measure the degree of curvature using at-home photography and an International Index of Erectile Function (IIEF-5) questionnaire. <b><i>Results:</i></b> A significant pain reduction at the end of the treatment in 51 (79.6%) patients (<i>p</i> < 0.01) of the treated group was observed. No significant improvements in the sham group (<i>p</i> = 0.23) have been observed. No statistical differences in the degree of curvature have been observed in both groups. No statistical improvements have been observed in the IIEF-5 questionnaire. Adverse events have not been reported. <b><i>Conclusion:</i></b> This is, to our knowledge, the first randomized, single-blind, sham-controlled study that shows that TCARE has a positive short-term clinical effect on pain in patients with PD. The feasibility and tolerability of this treatment produce an attractive new therapeutic option for men with PD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 | Urologia internationalis |